C-reactive protein levels in subjects with Prader-Willi syndrome and obesity

Genetics in Medicine

Volumn 8, Issue 4, 2006, Pages 243-248

  Butler, Merlin G ^a,b   Bittel, Douglas C ^a   Kibiryeva, Nataliya ^a   Garg, Uttam ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Biomarkers; Body mass index; C reactive protein (CRP); Cardiovascular disease; Obesity; Prader Willi syndrome (PWS)

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANTHROPOMETRY; ARTICLE; BEHAVIOR DISORDER; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEEDING DISORDER; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERPHAGIA; HYPOGONADISM; IMMUNOASSAY; INFANTILE HYPOTONIA; MALE; MENTAL DEFICIENCY; OBESITY; PRADER WILLI SYNDROME; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; ANTHROPOMETRY; BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; CHILD; COHORT STUDIES; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; OBESITY; PRADER-WILLI SYNDROME; SEX FACTORS; WAIST-HIP RATIO;

EID: 33646778165     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000204469.30913.67     Document Type: Article

References (38)

1. Tillet W, Francis T. Serologic reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930;52:561-571.
2. Abernathy TJ, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. I. Distribution of the reactive protein in patient's sera and the effect of calcium on the flocculation reaction with C-polysaccharide of pneumococcus. J Exp Med 1941;73:173-182.
3. Schultz Dr. Arnold PI. Properties of four acute phases proteins: CRP, serum amyloid A protein, -acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 1990;20:129-147.
4. Osmand AP, Friedeson B, Gewurz H, Painter RH, et al. Characterization of C-reactive protein and the complement subcomponent Clt as homologous proteins displaying cyclic pentameric symmetry (pentraxins). Proc Nat Acad Sci USA 1977;74: 739-743.
5. Tietz NW editor. Clinical guide to Laboratory Tests. 3rd ed. Philadelphia: WB Saunders, 1995:358.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336: 973-979.
7. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
8. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932-940.
9. Oanesh J, Wheeler JG, Hirschfield GM, Eda S, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
10. Visser M, Bouter LM, McQuillan GM, Wener MH, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135.
11. Tchernof A, Nolan A, Sites CK, Ades PA, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-569.
12. Ziccardi P, Nappo F, Giugliano G, Esposito K, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002;105:804-809.
13. MacGregor AJ, Gallimore JR, Spector TO, Pepys MB. Genetic effects on baseline values of C-reactive protein and serum amyloid A protein: a comparison of monozygotic and dizygotic twins. Clin Chem 2004;50:130-134.
14. Carlson CS, Aldred SF, Lee PK, Tracy RP, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005;77:64-77.
15. Butler MG. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 1990;35:319-332.
16. Cassidy SB, Oykens E, Williams CA. Prader-Willi and Angelman syndromes: sister imprinted disorders. Am J Med Genet 2000;97:136-146.
17. Cassidy SB, Schwartz S. Prader-Willi Syndrome. GeneReviews 2005; http://www. genereviews.org.
18. Bittel DC, Butler MG. Prader-Willi syndrome: clinical genetics, cytogenetics and molecular biology. Expert Rev Mol Med 2005;7:1-20.
19. Nicholls RD, Knoll JH, Butler MG, Karam S, et al. Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature 1989;342: 281-285.
20. Lamb AS, Johnson WM. Premature coronary artery atherosclerosis in a patient with Prader-Willi syndrome. Am J Med Genet 1987;28:873-880.
21. Page SR, Nussey SS, Haywood GA, Jenkins JS. Premature coronary artery disease and the Prader- Willi syndrome. Postgrad Med J 1990;66:232-234.
22. Eiholzer U. Prader-Willi syndrome: effects of human growth hormone treatment. In: Savage, MO. ed. Endocrine Development Series, Vol. 3, 2001: Basil, Switzerland: Karger.
23. Kuromaru R, Kohno H, Ueyama N, Hassan HM, et al. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: Gender-specific metabolic effects. J Clin Endocrinol Metab 1998;83:3890-3896.
24. L' Allemand D, Schlumpf M, Torresani T, Girard J. Insulin secretion before and under 3 years of growth hormone (GH) therapy in Prader- Willi syndrome (PWS) (abstract). Exp Clin Endocrinol Diabetes 2000;108:127.
25. Ruvalcaba RH, Holm V. Effects of growth hormone in Prader-Willi syndrome. A case report. Clin Pediatr 1993;32:292-295.
26. Goldstone AP, Thomas EL, Brynes AE, Bell JD, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 2001;86(9):4330-4338.
27. Talebizadeh Z, Butler MG. Insulin resistance and obesity-related factors in Prader-Willi syndrome: comparison with obese subjects. Clin Genet 2005;67:230-239.
28. Hoybye C, Bruun IM, Richelsen B, Flyvbjerg A, et al. Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. Eur J Endocrinol 2004;151:457-461.
29. Kennedy L, Bittel DC, Kibiryeva N, Kalra SP, et al. Circulating adiponectin levels, body composition and obesity-related variables in Prader-Willi syndrome: Comparison with obese subjects. Int J Obes 2005; Advance online publication: 4 October, 2005.
30. Jewell WS, Marnell LL, Rokeach LA, Du Clos TW. C-reactive protein (CRP) binding to the Sm-D protein of snRNPS. Identification of a short polypeptide binding region. Mol Immunol 1993;30:701-708.
31. Pepys MB, Booth SE, Tennent GA, Butler PJ, et al. Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol 1994;97:152-157.
32. Thompson T, Butler MG. Prader-Willi syndrome. Clinical, behavioral and genetic findings. In:Wolraich, ML ed. Disorders of Development and Learning, 3rd Edition 2003: Hamilton, Canada: B.C. Decker, Inc.
33. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, et al. CDC growth charts: United States. Adv Data 2002;8:1-27.
34. SPSS Inc. SPSS Statistical Software System, Version 10.1. IL: Chicago, 2000.
35. Pearson T, Mensah G, Alexander RW, Anderson JL, et al. Markers of inflammation and cardiovascular disease. Circulation 2003;107:499-511.
36. Dixon JS, Bird HA, Sitton NG, Pickup ME, et al. CRP in the serial assessment of disease activity in rheumatoid arthritis. Scand J Rheumatol 1984;13:39-44.
37. Hind CR, Pepys MB. The role of CRP measurement in clinical practice. Int Med 1984;5:112-151.
38. van Leeuwen MA, van Rijswijk MH. Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin Rheumatol 1994;8:531-552.